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Abstract
Presbycusis (hearing loss that occurs with age) affects 30% of adults aged 65 to 74, yet hearing
loss is rarely considered when developing novel treatment deliveries. For example, research
shows that telepsychiatry improves depression symptoms among geriatric patients similarly to
traditional forms of therapy, however, there is no literature on effectiveness of telepsychiatry in
geriatrics with presbycusis. The objective of this study is to assess whether, compared to face-toface psychotherapy, telepsychiatry produces superior outcomes assessed by the Beck Depression
Inventory II, among depressed geriatric patients suffering from presbycusis. We will conduct a
randomized controlled trial among elderly individuals with depressive disorders and presbycusis
who will be randomly allocated to 8 weekly, 60-minute manual sessions of Behavioral
Activation Therapy for Depression either in the clinic or in the participants’ home, using
telepsychiatry. This study will help guide future therapies directed towards the growing geriatric
population, many of whom suffer from presbycusis.
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Chapter 1 – Introduction
Background
Telemedicine is the electronic transfer of medical and health information between distant
sites and participants.1 It has seen tremendous growth in the information age and has been
successfully applied across various fields of medicine.2-4 Technological advances that have made
the relevant equipment less expensive and easier to use have stimulated so much interest and
success in telemedicine that it is now a well-accepted method of diagnosis and treatment.5
Telepsychiatry—the delivery of healthcare and the exchange of healthcare information
for the purposes of providing psychiatric services across distances6—has grown rapidly probably
due to the easy adaptation of traditional talk therapy to delivery via telemedicine, specifically
video-based telemedicine. Telepsychiatry review articles indicate that this form of medicine
increases access to care, yields improved patient outcomes and leads to increased patient
satisfaction.7
Many studies have examined the effectiveness, feasibility and acceptability of
telepsychiatry, which has been successfully used in veterans with post-traumatic stress disorder,8
Alzheimer’s dementia,9 and other mental health disorders.10 However, more research is needed
on clinical outcomes of telepsychiatry treatment models.7
Telepsychiatry has also been studied in various patient populations, but the geriatric
population will likely benefit the most from the services. It is expected that 22% of Americans
will be aged 65 or older by 2050, and the number of people who are 85 years and older is
expected to nearly double by 2035.9 Additionally, the geriatric population is at a higher risk of
mood disorders such as depression – with as many as 49% of nursing home residents suffering
from depression, 35% of those affiliated with in home health agencies and 25% in residential
1

care communities.12 The elderly also make up a large portion of patients from rural and remote
locations and often have multiple chronic conditions, a situation which limits their ability to
access specialized care.19 Even though depression is prevalent and the geriatric population is
growing, access to geriatric psychiatrists is decreasing.5 These factors have created a need for
telepsychiatry to bridge the gap between patients and providers.10 Telepsychiatry has the ability
to connect psychiatrists to older adults in underserved or remote areas who would otherwise be
unable to travel to the psychiatrist for treatment.
Statement of Problem
Telepsychiatry is a mainstream form of treatment used to address mood disorders in adult
populations. Hearing loss affects 30% of adults aged 65 to 74, and 47% of adults over the age of
74.13 Several studies have evaluated the effectiveness of telepsychiatry in the elderly population,
but none has measured presbycusis and its impact on treatment outcomes in elderly patients with
mood disorders such as depression.
Objective
The purpose of our study is to assess whether telepsychiatry is superior to traditional
face-to-face therapy among depressed geriatric patients suffering from presbycusis.

Hypothesis
We hypothesize that Beck Depression Inventory II scores in depressed geriatric
participants suffering from presbycusis will decrease from baseline to post-treatment clinically
significantly more in the telepsychiatry group compared to the face-to-face group.
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Definitions
Telemedicine: Electronic transfer of medical and health information between distant sites and
participants.1
Telepsychiatry: The delivery of healthcare and the exchange of healthcare information for the
purposes of providing psychiatric services across distances.6
Presbycusis: A progressive, bilateral and symmetrical sensorineural hearing loss due to age
related degeneration of inner ear structures.21
Depression: Depressed mood and/or loss of interest or pleasure in life activities for at least two
weeks and at least five of the following symptoms that cause clinically significant impairment in
social, work, or other important areas of functioning almost every day: Depressed mood most of
the day, diminished interest or pleasure in all or most activities, significant unintentional weight
loss or gain, insomnia or sleeping too much, agitation or psychomotor retardation noticed by
others, fatigue or loss of energy, feelings of worthlessness or excessive guilt, diminished ability
to think or concentrate, or indecisiveness, recurrent thoughts of death.20
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Chapter 2 – Review of Literature
Introduction
To assess the current status of telemedicine in the geriatric population, we
performed a review of the literature in the English language from January 2003 to
December 2018 using Scopus and PubMed. The following search terms were used:
(((telemedicine OR tele mental health OR telehealth OR tele-psychology OR tele
psychology)) AND (older adults OR geriatrics OR veterans)) AND (depression) OR
hearing loss) OR (presbycusis)))). We also performed a manual search of references from
review articles.

Screening

Identification

Figure 1. Literature Review Flow Diagram
Records identified
through database
searching (n =245)

Additional records
identified through other
sources (n = 7)

Records after duplicates removed
(n = 252)

Included

Eligibility

Records screened (n = 252)

Full-text articles assessed
for eligibility (n = 48)

Studies included in qualitative synthesis (n = 13)
4

Records excluded
(n = 204)

Full-text articles
excluded, with
reasons (n = 35)

Inclusion criteria were as follows: the article had to test the outcomes of a videobased form of telepsychiatry. The interventions had to include an accepted form of
depression treatment (e.g. psychotherapy, medication management, etc.) in adult
populations over the age of 18. Exclusion criteria included review articles, studies using
telephone-based or automated interventions, deaf populations, and studies that did not
assess patient outcomes as the main outcome variable.
Once duplicates were removed a total of 252 articles remained and were screened
for relevance using titles and abstracts. After screening articles based on titles and
abstracts, 48 remained and were screened for the inclusion and exclusion criteria stated
above. Thirteen articles remained for review. Of these, two papers described pilot studies
prior to their subsequent randomized controlled trials (RCT); we focused only on the
paper describing the final RCT. Two articles were excluded based on their inclusion of
deaf individuals for telepsychiatry treatment interventions1,2 and no there were no articles
that explicitly examined patients with hearing loss. Therefore, we focused on the
available studies investigating the utilization of telepsychiatry for the treatment of
depression in adults.
The next section will briefly summarize the study designs and methods used
followed by a more detailed analysis broken down by study design topic.
Study Design
Within the telepsychiatry literature, individual psychotherapy was examined in 13
studies, including 6 randomized controlled trials,3-8 one randomized, open-label trial,9
three pilot studies3,10,11 and three observational studies.12-14 Among the randomized trials,
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3 were superiority designs,6,7,15 2 were non-inferiority designs8,9 and 2 were equivalence
designs.3-5
Randomized Controlled Trials
Superiority Randomized Controlled Trials
Ruskin et al.6 were the first authors to perform a large scale RCT in 2004
comparing telepsychiatry to in-person treatment of psychiatric illnesses in which they
found no difference between treatment conditions. They recruited 119 participants from
the Maryland Veterans Association. The treatment consisted of eight, 20-minute sessions
with a psychiatrist over a 6-month period. Sessions addressed antidepressant medication
management, psychoeducation and brief supportive counseling.
In 2006, De Las Cuevas et al.,7 performed a RCT of 130 participants recruited
from the Community Mental Health Centre of San Sebastian de la Gomera, in the Canary
Islands and found no difference in outcome measures between face-to-face and
telepsychiatry groups. The intervention was similar to that of Ruskin’s,6 consisting of
eight, 30-minute sessions over 24 weeks and also required patients in both the face-toface and telepsychiatry groups to report to the same location for their care. But the
authors7 differ by using a single provider for both the intervention and treatment as usual
groups. This method allowed for more control of the patient-provider relationship, an
important determinant for health outcomes, and also increased the internal validity of the
study. However, using the same provider also introduces bias as the provider may favor
one method over the other and unconsciously alter his/her interactions with patients.
In 2013, Lichstein et al.10 underwent a pilot study which eventually led to the 21participant RCT completed by Scogin et al.16 in 2018. The authors assessed whether
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treatment of comorbid depression and insomnia by therapists through telepsychiatry
resulted in better clinical outcomes than usual care with a primary care practitioner
(PCP). There was no difference between experimental and control groups on a depression
and sleep outcome measures.
None of these three superiority RCTs found statistically significant differences
between the face-to-face and telepsychiatry groups. Even though these studies are
powered to detect statistically significant differences between treatment groups based on
comparative methods rather than equivalence methods, often their authors incorrectly
conclude that non-significant differences between groups implies equivalence. In order to
address this issue, two subsequent authors present equivalency RCTs.
Equivalence Randomized Controlled Trials
O’Reilly et al.5 specifically designed and powered an equivalence study to
determine whether telepsychiatry consultations for depression, which included optional
monthly follow-up sessions for up to 4 months, were not inferior to face-to-face delivered
sessions. 286 participants completed the study; equivalence was demonstrated between
the telepsychiatry and face-to-face groups.
Similarly, Choi et al.4 presents two studies, a preliminary efficacy trial and a
subsequent equivalence RCT with 116 participants. Both studies report on the same
experiment at different time points. The study design is a three-arm randomized control
trial where the control group received 30 minute “support calls” from social workers,
while the two treatment groups received six 60-minute face-to-face or telepsychiatry
sessions focusing on problem solving therapy. This method differs from the previous
studies in that a “true” control group is used in addition to the face-to-face comparison
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group. The authors found that at follow-up, the telepsychiatry group had improved more
than face-to-face and control groups on depression and disability measures. Although the
difference was not statistically significant, the authors were unable to reject the null
hypothesis of equivalence between telepsychiatry and face-to-face groups.
The previous two studies used equivalence methods to determine whether the
telepsychiatry intervention is neither worse nor better than face-to-face treatment or
control condition. Equivalence trials are often confused with non-inferiority trials, whose
main goal is to determine whether a new intervention is inferior to another or established
intervention. Inferiority trials use a defined non-inferiority margin, based on clinical
judgement and statistical considerations, which defines the limit of acceptable inferiority.
Often non-inferiority designs are implemented for novel approaches to current successful
therapies but may be beneficial or superior in other ways. For example, telepsychiatry has
been shown to be as effective as face-to-face therapy, but it may also provide additional
benefits such as decreased travel time, costs and increased accessibility. The following
two studies implement a non-inferiority design.
Non-inferiority Randomized Controlled Trials
Egede et al.9 performed a non-inferior RCT in 2015 to assess telepsychiatry
amongst older veterans suffering from depression compared to face-to-face treatment.
They randomized 241 participants to either telepsychiatry or face-to-face therapy; 204
participants completed the study. Using a non-inferiority margin of 15%, they found the
telepsychiatry treatment to be non-inferior to face-to-face treatment.
The following year, Luxton et al.8 published a non-inferior RCT in which they
randomized 121 military service members and veterans into home tele-therapy or face-to-
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face therapy (82 completed the study). Authors found slightly better results for in-person
visits, but the difference was not statistically significant and based on the non-inferiority
analysis, the null hypothesis could not be rejected. Thus, the study concluded that inhome telepsychiatry was no worse than face-to-face psychotherapy.
Observational Studies
While RCTs are the “gold standard” of trials, they are often expensive, timely and
difficult to achieve. Researchers can also draw valid conclusions from observational
studies especially when an such a study is well designed and may even better reflect the
“real world” than some RCTs. The following authors performed observational studies.
Kennedy et al.12 recruited 124 participants who were referred for mental
healthcare through telepsychiatry and compared them to those being seen face-to-face in
rural Queensland. Participants were not randomized in this observational study and the
effect of treatment was evaluated using the Mental Health Inventory (MHI)17—a 38-item
self-reported measure of mental health issues—completed by participants, and Health of
the Nation Outcome Scales (HoNOS)17—a 12-scale, clinician-rated measurement of
health and social functioning, completed by practitioners. They found an improvement in
both groups from baseline to post-treatment, but the groups did not differ statistically
significantly.
Griffiths et al.13 performed an observational study among 18 participants with
depression and/or anxiety in Queensland that tested the effects of 6 to 8 weekly
telepsychiatry CBT sessions had on clinical outcomes. They found statistically significant
improvements from baseline to post-treatment among 48 participants. No control or
comparison group was used.
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Urness et al.14 measured patients’ satisfaction and patient outcomes in an
observational study of patients receiving either face-to-face mental health or
telepsychiatry care (not randomized). The telepsychiatry group showed a statistically
significant improvement in pre- and post-intervention scores, while the face-to-face
group did not. These difference between groups was not analyzed.
The results obtained from these observational studies have limitations. For
example, even though Urness et al.12 found improvements in the telehealth group and not
in the face-to-face group, there may be some confounding factors between the groups that
were not neutralized because of the study design. Furthermore, Kennedy et al.12 found
improvements from baseline but it is not known whether these improvements were due to
the intervention or may have occurred by chance given the lack of a control group.
Case Studies
Lastly, Lazzari et al.11 performed a small pilot study examining the effectiveness
of Behavioral Activation Treatment for Depression (BATD) in older adults. In this study
two out of the three patients improved sufficiently and no longer met the criteria for
depression by post-treatment. All patients reported satisfaction with treatment by
videoconferencing. Since the pilot study included only 3 participants, it is limiting in its
ability to extrapolate findings to the general population.
Patient Selection
In general, recruitment of participants for the eleven studies occurred through the
use of new or existing referrals for outpatient treatment of depression or self-referrals
through print and radio advertisements,5,6,8,12,14 electronic medical records,7,9,15 case
manager referrals3,4 and purposive sampling.11
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Several studies recruited participants from the Veterans Affairs Medical
Center.6,8,9 One study recruited participants by mailing postcards to a mailing list,
requesting that patients contact study coordinators if they felt that they were sad or
depressed and were interested in participating in a clinical trial.9
While the structure of the VA system provides easier avenues for patient
recruitment, study trial participants are often homogeneous, leading to sample bias. For
example, the majority of the VA participants in the Ruskin et al.6 trial were male (88%)
and Caucasian (61%). Similarly, Egede et al.9 and Luxton et al.8 had comparable
participant characteristics: 98% and 82% of their sample was male, and Caucasian (60%
and 70%, respectively). Thus, women and minorities were vastly underrepresented in
these samples and there were likely other characteristics within these groups that may
present confounding factors.
Another popular method of recruitment was through referrals from other health
agencies or systems5,7,11-14,16 resulting in a participant pool already being seen in an
existing healthcare system. This method of recruitment does not allow researchers to
include patients who have not sought treatment for their mental health due to inability to
access care or fear of stigmatization.
In contrast, Choi et al.4 recruited patients through referrals from “Meals on
Wheels” and other agencies serving low income seniors in Texas. Only older adults who
were both low income and homebound were referred. This unique method targeted
populations most in need of telehealth services – low income, homebound elderly adults
who were not necessarily already being seen in the healthcare system.
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Although we believe that older adults will benefit most from telehealth services,
many of the studies included in this review excluded them. Specifically, a few studies
consisted of adult populations with ages ranging from eighteen to sixty-five,5,8 eighteen
to sixty14 or eighteen to fifty.6 Only two authors did not cap the upper age limit,7,12 and
only three studies focused on the older population by including ages over 50, 58 and 65.
4,11,15

One study did not supply information about the age of participants.13 In Luxton’s et

al.8 study, a large portion of participants were employed and were required to leave work
in the middle of the day to go home for their therapy session, which presents an obstacle
for an employed adult. In short, it is clear that further studies with more diverse
populations and a focus on older adults is warranted.
Table 1. Summary of Studies
Author

Study Design

Sample
Size
124

Objective

Method

Findings

Kennedy et
al. (2003)12

Observational

To compare
telepsychiatry to
face-to-face
psychiatry
among rural,
depressed
patients

CBT sessions
followed by inperson reinforcement
with case managers

Superiority
RCT

119

To compare
face-to-face
psychiatry to
telepsychiatry
among depressed
patients

Superiority
RCT

140

To compare
face-to-face
psychiatry to
telepsychiatry
among depressed
patients

8 20-minute sessions
addressing
psychoeducation,
supportive
counseling,
medication
management of over
the course of 6
months
8 30-minute sessions
of CBT and
medication
management over 24
weeks delivered

Improvements in
both MHI and
HoNOS scores from
baseline to posttreatment (p<0.01)
but no difference
between groups in
MHI (p=0.7) or
HoNOS (p=0.4)
Both groups had
improvement in
depressive
symptoms
(p<0.001). No
difference between
groups

Ruskin et
al.
(2004)6

De Las
Cuevas et
al. (2006)7

12

Improvement in
both CGI and SLC90R scores from
baseline to posttreatment in both
groups (p<0.001).
No difference
between groups
(2= 0.4, df=1)

Griffiths et
al. (2006)13

Observational

15

To compare
face-to-face
psychiatry to
telepsychiatry
among patients
with depression
and/or anxiety

6-8 weekly CBT
sessions (type of
CBT depended on
diagnosis) followed
by in-person
reinforcement with
case managers

Improvements in
both MIH and
HoNOS scores from
baseline to posttreatment (p<0.05,
p<0.05,
respectively)

Urness et
al. (2006)14

Observational

48

To compare
face-to-face
psychiatry to
telepsychiatry

Traditional
psychotherapy
sessions. No specific
type was described
by authors

O’Reilly et
al. (2007)5

Equivalence
RCT

286

To compare
face-to-face
psychiatry to
telepsychiatry
among depressed
patients

Psychiatric
consultation with
recommendations
provided to PCP with
optional month
follow-up

Lazzari et
al. (2011)11

Uncontrolled
Pilot Study

3

Five 1-hour BATD
sessions at
psychiatric clinic

Choi et al.
(2014)4

3-arm
Equivalence
RCT

158

Egede et al.
(2015)9

Noninferiority
RCT

241

To compare
face-to-face
psychiatry to
telepsychiatry
among depressed
elderly
To compare
telepsychiatry to
face-to-face
psychiatry and
control support
calls among lowincome,
depressed elderly
To compare
telepsychiatry to
face-to-face
psychiatry
among depressed
veterans

Telepsychiatry
group showed
improvement from
baseline to posttreatment in MCS
measure (p=0.001)
but not PCS
(p=0.28). Face-toface group did not
show improvement
in either score.
Both groups showed
improvements in
BSI score at followup and per protocol
analysis revealed
equivalence of
telepsychiatry to inperson psychiatry
Two out of three
patients no longer
met criteria for
depression by posttreatment

Luxton et
al. (2016)8

Noninferiority
RCT

121

To compare
telepsychiatry to
face-to-face

50 to 60-minute
BATD sessions for

13

Six 60-minute PST
session via video
conferencing or inperson and control
group received 30minute support calls
from social workers
60-minute weekly
BATD sessions over
8 weeks

Both in-person and
tele-PST were more
effective than
control support calls
based on HDS
scores
(p=.001, p=.001,
respectively)
No evidence for
non-inferiority of
telepsychiatry to
face-to-face therapy.
Both continuous and
dichotomous
outcome measures
show nonsignificant
differences in GDS
(p= .4058) and BDI
(p=0.5169)
No evidence of
inferiority of

psychiatry
among depressed
veterans

Scogin et
al. (2018)16

Superiority
RCT
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To compare
usual care with
PCP to
telepsychiatry
among patients
with comorbid
depression and
insomnia

10 sessions of
integrated CBT-D
and CBT-I performed
by graduate students

telepsychiatry to
face-to-face therapy.
Non-significant
reductions in BDI-II
and BHS in the ITT
sample
Non-significant
decrease in HDS
scores from baseline
to post-treatment
(p=0.14)

Abbreviations: CBT: Cognitive Behavioral Therapy, MHI: Mental Health Inventory, HoNOS: Health of the Nation
Outcome Scale, CGI: Clinical Global Impression, SLC-90R: Symptoms Checklist-90-Revised, MCS: Mental
Component Score, PCS: Physical Component Score, BSI: Brief Symptom Inventory, BATD: Behavioral Activation
Therapy for Depression, PST: Problem Solving Therapy, GDS: Geriatric Depression Score, BDI: Beck Depression
Inventory, BDI-II: Beck Depression Inventory-II, BHS: Beck Hopelessness Scale, ITT: Intention to Treat, PCP:
Primary Care Provider, CBT-D: Cognitive Behavioral Treatment for Depression, CBT-I: Cognitive Behavioral
Treatment for Insomnia, HDS: Hamilton Depression Scale

Inclusion Criteria
Five of the eleven articles had inclusion criteria consisting of major depression
disorder (or other similar diagnosis such as dysthymic disorder or generalized anxiety
disorder) as diagnosed by DSM-IV criteria.6,8,9,11,13 Two studies based their inclusion
criteria on the Hamilton Depression Scores (HDS):18 Ruskin et al.6 included participants
who scored a 16 or higher on the HDS while Choi et al.4 included those who scored a 15
or higher on the HDS. O’Reilly et al.5 used a score above 63 on the Brief Symptom
Inventory (BSI)19 to determine participant eligibility.
Some studies did not narrow their inclusion criteria to any mental illness but
rather included all patients who were referred by any source and identified by a
practitioner as having a mental disorder, requiring mental health services.12,14,16 Such
broad inclusion criteria with no specific diagnosis increases the generalizability of the
study, but decreases the internal validity making it difficult to identify the effect
treatment had on participants with a depression diagnosis.
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In addition, one study did not implement a systematic way to evaluate participants
for their inclusion diagnosis – Scogin et al.16 limited participants to those who had both
depression and insomnia, but the participants were not required to have an official
diagnosis of depression or insomnia. Instead they were required to have symptoms that
were severe enough to require ongoing treatment from their primary care practitioner.
Because participants were not diagnosed with depression or insomnia through the study
protocol, it is arguable that this inclusion criterion is not robust and possibly led to bias in
patient selection.
Exclusion Criteria
Authors excluded participants who met criteria for bipolar disorder,3,6 substance
abuse or dependence,4,6,8,9,16 psychosis, 4,6,8,9,11,16 suicidal ideation or selfharm,4,9,11,13,14,16,20 or if they were currently receiving psychotherapy8,11,16,21 or
pharmacotherapy for depression.6
Two authors excluded participants who demonstrated visual or hearing
impairment (impairments were not operationalized or measured directly).4,11
Furthermore, most authors did not take into account common disabilities in the elderly
(such hearing loss, vision loss or decreased fine-motor skills) that impact their capability
to use telehealth services. By failing to take into account confounding factors such as
disabilities commonly found in certain patient populations, it is difficult for authors to
draw accurate conclusions in their data.
Table 2. Recruitment and Inclusion and Exclusion Criteria
Author
Kennedy et al.
(2003)12

Age
>18

Population/Recruitment
Consecutive sampling
of patients being seen
by practitioners for
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Inclusion Diagnosis
Any psychiatric
disorder requiring
mental health services

Exclusion Diagnosis
None

mental healthcare in
rural Queensland
Veterans referred for
outpatient treatment

Ruskin et al.
(2004)6

18-50

MDD, Dysthymia,
adjustment disorder,
depressed mood, not
otherwise specified
(DSM-IV)
HDS >15

De Las
Cuevas et al.
(2006)7

>18

Consecutive
psychiatric outpatients
referred from PCP

Griffiths et al.
(2006)13

N/A

Recruited through case
managers

Urness et al.
(2006)14

18-60

O’Reilly et al.
(2007)5

18-65

Recruited from existing
patients from 11 sites
offering tele- or inperson psychiatric
treatment in Alberta,
CA
Referrals from PCP in
Ontario, CA

Lazzari et al.
(2011)11

>64

Purposive sampling of
patients from
psychiatry clinic

MDD or dysthymia
(DSM-IV)

Choi et al.
(2014)4

>50

Homebound, served by
senior agencies

HDS>14

Egede et al.
(2015)9

>58

MDD (DSM-IV)

Luxton et al.
(2016)8

18-65

Veterans from VA
hospital and four
associated outpatient
clinics
Active duty members,
reserve, national guard

Scogin et al.
(2018)16

>50

Patients were recruited
from primary care
clinics in mid-western
Alabama

Agreement of PCP of
the presence of
depression and
insomnia with
symptoms significant
enough to warrant
treatment

Substance abuse,
psychosis, mood d/o,
somatoform d/o, adult
personality and
behavior d/o (ICD-10)
MDD or mixed anxiety
and depressive d/o,
GAD, panic d/o with
agoraphobia (ICD-10)
No specific diagnosis
but no psychotherapy
for at least 6 months
before initial
consultation
BSI >62

MDD (DSM-IV)
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Bipolar, schizophrenia,
substance abuse or
dependence in past year,
current pharmacological
treatment for depression
for > 1 month before
initial visit
None

Severe comorbid
conditions, high risk of
self-harm, poor English
skills
Referred urgently,
unable to consent,
physically aggressive,
agitated or suicidal

If PCP believed them
unable to consent, or if
patients were referred for
medico-legal issues
Psychosis, SI, cognitive
impairment, currently
receiving psychological
treatment, audio or
visual impairments
Psychosis, dementia, SI,
bipolar, substance
addiction, audio or visual
impairments
Psychosis, dementia, SI,
current substance use or
dependence
Psychosis, SI, current
substance use or
dependence, currently
enrolled in
psychotherapy for
depression
Psychosis, SI, current
substance use or
dependence, cognitive
impairment or currently
receiving psychological
treatment

Abbreviations: MDD: Major Depressive Disorder, DSM-IV: Diagnostic and Statistical Manual of mental disorders, 4th
edition, HDS: Hamilton Depression Scale, ICD-10: International Classification of Disease, GAD: Generalized Anxiety
Disorder, BSI: Brief Symptom Inventory, PCP: Primary Care Provider, SI: Suicidal Ideation

Outcome Measures
Depression was the primary outcome measure in all the studies included in the
review. There are numerous validated outcome measurement tools for depression in the
literature which include short assessments made by the provider, extensive self-reported
surveys/questionnaires and clinician-delivered interviews, to name a few.
Within our literature review, authors used the Hamilton Depression Scale
(HDS),3,4,6,10,15 Geriatric Depression Score (GDS),9,11,22 Clinical Global Impression (CGI)
ratings, Short Form Health Survey (SF-12),9,14,22 Brief Symptom Inventory (BSI),5 Beck
Depression Inventory-II (BDI-II),6,8,9,22 Beck Hopelessness Scale (BHS)8, Symptom
Checklist-90 Revised (SCL-90R)7, Structured Clinical Interview for Depression
(SCID),9,22 Patient Health Questionnaire (PHQ-9),15 Mental Health Inventory (MHI)12,23
and Health of the Nation Outcome Scale (HoNOS).12,13
The most commonly used outcome measure of depression is the Hamilton
Depression Score (HDS).4,6,16 Ruskin et al.6 used this 24-item scale in addition to
measures of treatment adherence, patient satisfaction, psychiatrist satisfaction and
resource consumption. Choi et al.4 used a modification of the Hamilton scale which
included three additional items measuring hopelessness, helplessness and worthlessness.
The efficacy of treatment in De Las Cuevas et al.’s7 study was measured with the
Symptom Checklist-90 Revised (SCL-90R)24 global distress indexes and the Clinical
Global Impression (CGI)25 ratings. The CGI is administered in approximately 2-minutes
by the study psychiatrist and uses a 7-point Likert scale to assess severity of illness and
global improvement. The CGI also does not assess for depressive symptoms but rather
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relies heavily on the subjective evaluation of the clinician to assess for improvement in
symptoms. Because the scale does not use more concrete markers for improvement and is
performed by the patients’ psychiatrist, it is highly susceptible to bias because it cannot
be assessed blindly. The SCL-90R is a self-reported, 5-point Likert scale measure,
encompassing a broad range of psychological problems. While gathering data on such a
broad range of issues is advantageous for assessing the psychological health of a patient,
it may not be specific enough for evaluating depression-specific symptoms, which is the
primary outcome of interest.
Table 3. Outcome Measures
Author
Kennedy et al.
(2003)12

Primary Outcome
MHI17: 38-item self-reported survey measuring distress and well-being
HoNOS17: 12-item survey completed by clinicians, measuring behavior, symptoms
and social functioning

Ruskin et al.
(2004)6

HDS18: 17-item questionnaire administered by clinician on a Likert scale to assess
severity of depression.

De Las Cuevas
et al. (2006)7

SCL-90R22: Self-reported measure of psychological improvement based on 5-point
Likert scale
CGI25: Assesses treatment response in all categories of psychiatric patients;
administered in 2-minutes by clinicians

Griffiths et al.
(2006)13

MHI:17 38-item self-reported survey measuring distress and well-being
HoNOS:17 12-item survey completed by clinicians, measuring behavior, symptoms
and social functioning

Urness et al.
(2006)14
O’Reilly et al.
(2007)5

SF-12:27 12-item self-reported survey of health

Lazzari et al.
(2011)11

GDS26: 30-item self-report assessment used to identify depression in the elderly

BSI5: 53-item self-report of psychological symptoms and measures distress from
these symptoms.

PANAS:27 A self-report questionnaire that consists of two 10-item scales to measure
both positive and negative affect based on 5-point Likert scale
Q-LES-Q:28 A self-report measure designed to enable investigators to easily obtain
sensitive measures of the degree of enjoyment and satisfaction experienced by
subjects in various areas of daily functioning
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Choi et al.
(2014)4

Modified HDS: 17-item questionnaire administered by clinician on a Likert scale to
assess severity of depression. Modification included three additional items measuring
hopelessness, helplessness and worthlessness
SF-12:29 12-item self-reported survey of health

Egede et al.
(2015)9

SCID:30 Diagnostic exam used to determine psychological disorders
BDI-II:31 21-question multiple-choice self-reported inventory of depression
GDS:26 30-item self-report assessment used to identify depression in the elderly

Luxton et al.
(2016)8

BHS:32 20-item self-report inventory used to assess hopelessness
BDI-II:33 21-question multiple-choice self-reported inventory of depression

Scogin et al.
(2018)16

HDS:18 17-item questionnaire administered by clinician on a Likert scale to assess
severity of depression
ISI:34 7-item self-reported questionnaire based on 7-point Likert scale used to assess
the nature, severity, and impact of insomnia in adults

Abbreviations: MHI: Mental Health Inventory, HoNOS: Health of the Nation Outcomes Scale, HDS: Hamilton
Depression Scale, BSI: Brief Symptom Inventory, SLC-90R: Symptoms Checklist-90 Revised, CGI: Clinical Global
Impression , SF-12: Short Form-12, BSI: Brief Symptoms Inventory, GDS: Geriatric Depression Scale, PANAS:
Positive Negative Affect Schedule, Q-LES-Q: Quality of Life Enjoyment and Satisfaction Questionnaire , SCID:
Structured Clinical Interview for DSM-IV, BDI-II: Beck Depression Inventory-II, ISI: Insomnia Severity Index

Sample Size
Studies vary in their sample sizes from 3 participants11 to 286 participants5 with
an average of 100 participants (excluding case studies). Of the RCTs, drop-out rates
varied from 7% to 48%, with an average drop-out rate of 27%. In the only RCT limited to
elderly patients, most of the drop outs were due to hospitalizations, patients moving to
nursing facilities or death.4
Randomization and Blinding
Neither the three observational studies nor the case study in this review were
randomized or blinded. However, all the RCTs were randomized and often were further
stratified by baseline characteristics such as age,7 depression severity,7 race/ethnicity9,16
and recruitment site.8,16 Blinding of the RCTs occurred at baseline interviews9,16 and
outcome measures.5,8,9,16 In some cases, the assessors were not blinded to the treatment
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condition because questions were included that were specific to subject method – such as
the ease and accessibility of telemedicine technology – which did not apply to the faceto-face treatment groups. Nevertheless, assessors were blinded to the study hypothesis.4
Telemedicine Technology
The devices and equipment used for the transmission of telepsychiatry services
differed among the studies reviewed here. The most common method was through a
computer6,7 that had videoconferencing software installed and often included a
camera,6,8,13,16 headphones,4,16 or speakers.13 A majority of the studies provided the
telehealth sessions at a location other than the participants home such as at the local
hospital or mental healthcare facility.5-7,11-13,16 This design allows authors to control for
variables such as lighting, audio and privacy while also supporting on-sight technicians to
aide in issues with connectivity. However, it does not allow authors to assess some
positive effects of remote treatment such as convenience, reduced cost, reduced travel.
Luxton et al.8 performed one of the only studies with in-home treatment.
However, there were several limitations: the participants were middle-aged, employed
and were expected to leave work to return home to attend the session, which negates
many of the advantages that telehealth may offer in terms of accessibility and less fear of
stigmatization. Most problematically, participants also experienced substantial technical
difficulties in this study - out of all sessions, 36.3% were unable to initiate a webcam
connection and 35.7% required a phone call to resolve a technical issue.
All but one study9 connected to the Integrated Services Digital Network (ISDN)
line, providing a 384 kilobit per second transmission in most cases.5-7,14 In instances
where a slower bandwidth was used, the result was delays in both speech and
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movement.12,13 Participants in the Egede et al.9 trial used a videophone which was
connected via a standard telephone service that was simple and easy to use.
Table 4. Telemedicine Technology
Author
Kennedy et al.
(2003)12
Ruskin et al.
(2004)6

Technology
Venue 2000 and Swiftsite
systems, PictureTel
VTEL software with cameras
mounted on the monitors

Transmission
ISDN at 128
kbit/s
ISDN at 384
kbit/s

Location
Local mental healthcare
facility
Clinic

De Las Cuevas
et al. (2006)7
Griffiths et al.
(2006)13
Urness et al.
(2006)14
O’Reilly et al.
(2007)5
Lazzari et al.
(2011)11

Viewstation 512 polycom

ISDN at 384
kbit/s
ISDN at 128
kbit/s
ISDN at 384
kbit/s
N/A

University hospital

Choi et al.
(2014)4
Egede et al.
(2015)9

Luxton et al.
(2016)8

Scogin et al.
(2018)16

PC-based desktop with
speakerphones and camera
videoconferencing equipment
Polycom 512 View Station and
a Sony Trinitron screen
videoconferencing technology
and headsets provided by the
university
Provided with laptops and
headsets and used Skype
software
Videoconferencing via
analogue videophone (KMEA
TV500SP)

Provided with Dell M6500
laptop and video camera and
used Jabber video software (a
Cisco Systems product
Skype Technologies combined
with web cameras, a headset
and microphone

Mental health service facility
In home

N/A

Local mental healthcare
facility
University psychology clinic

N/A

In home

Standard
telephone
service at 18
frames per
second

In home

N/A

In home

N/A

Primary care office

Abbreviations: ISDN - Integrated Services Digital Network

Intervention
The interventions used in the studies include problem solving therapy,4
Behavioral Activation Treatment for Depression,8,9,11 medication management,
psychoeducation, supportive counseling referrals to short-term psychotherapy
programs,5,6,12 telepsychiatry consultations provided to primary care practitioners7 and
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Cognitive Behavioral Therapy.10,13 The number of sessions varied from five sessions11 to
ten session,16 lasting anywhere from 20 minutes7 to 60 minutes.4,8,9,11 Several studies had
follow-up periods ranging from 8 weeks16 to 12 months.9
One of the most commonly known and used forms of psychotherapy is Cognitive
Behavioral Therapy (CBT) which has been shown to be an effective treatment for many
psychological disorders including depression.35 The treatment involves the patient
recognition of unhelpful or distorted ways of thinking resulting in the modification of
these thoughts and behaviors.
In some studies, a remote certified psychologist delivered CBT sessions to
participants while case managers observed and then reinforced the intervention while
face-to-face with participants, following the session.12,13 The type of CBT delivered was
based on the participants diagnosis. Those with depression focused on problem-solving,
sleep, increasing activity and good eating behaviors.13 De Las Cuevas et al.7 incorporated
eight, 30-minute CBT and medication management sessions over a 24-week period.
In contrast, participants in the Scogin et al.16 study received CBT from graduate
students in clinical psychology who had 4 days of didactic and experiential instruction.
The limited training of graduate students providing psychotherapy is in contrast to other
studies who delivered treatment through trained and experienced therapists, often with
several years of experience with psychotherapy.
Only one study used problem solving therapy (PST),4 which focuses on
improving coping skills for high stress situations through instruction in specific problemsolving steps. PST was delivered over six, 60-minute weekly sessions. Trained social
workers provided both telehealth and in person visits.
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Psychiatric consultations were used in another study.5 The consultations were
administered to participants and a report was provided to the participants’ primary care
provider. Consultations included follow-up appointments with the psychiatrist for up to 4
months at monthly intervals if deemed clinically appropriate. The consultations
themselves consisted of medical management, psychoeducation, supportive counseling
and referrals to other local services such as psychotherapy. Psychiatrists were required to
travel by plane and stay overnight in hotels while consulting face-to-face. Because of
these travel commitments, psychiatrists may have been less likely to follow-up with faceto-face consultations given the vast difference in time commitment required, thus
increasing bias in treatment between the two groups. Furthermore, treatments varied
between patients resulting in perhaps a more generalizable study, but one that may lack
internal validity.
Along with CBT, Behavioral Activation Therapy for Depression (BATD) was
among the most popular intervention used in our review and has similar efficacy as
CBT.35 It was more likely to be implemented among Veterans – both Egede et al.9 and
Luxton et al.8 recruited participants from the VA and used BATD. Egede et al.9 reported
their study was “the first randomized control trial of manualized evidence-based
psychotherapy for depression in older adults with telemedicine” and differs from past
studies in that it focuses on a robust model of psychotherapy (as opposed to medication
management). Subsequent studies have taken this approach, using forms of
psychotherapy like CBT as discussed above. In Egede’s study, participants all received
behavioral activation for depression for weekly 60-minute sessions over 8 weeks.9
Patients also used daily planners and activity lists to reinforce scheduling of behaviors
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that were of value to the patient. Much like the Egede study,9 participants in Luxton’s8
study were provided with 50 to 60-minute behavioral activation treatment for depression
every week for 8 weeks.
Data Analysis
Across all the papers reviewed, mixed effects models were the most common
analytic technique. In order to test for the significance of the difference between
treatment and control groups, most studies used mixed effects models with a repeated
measure design and used the significance of the interaction between treatment condition
and time as the key outcome.4,6,9,21,36 This statistical method is well suited to the
answering the key research question as it allows for significance testing of the treatment
condition as well as allows the researchers to account for the change in effect of
treatment condition over time. Mixed effects models also allow researchers to control for
confounding factors such as initial depression severity or demographics like gender and
age. One limitation of this method is that compared to simpler statistical methods it
usually requires larger samples sizes.
We also found that chi-squared tests were a popular method: to use this method
researchers dichotomized the outcome measure (typically splitting patients into those
who experienced clinical remission and those who did not). The chi-squared test allows
researchers to test whether the proportion of patients experiencing remission differed
between the treatment and control groups; this method was often used as a complement to
mixed effects models.6,7,12,16 Finally, several studies also used T-tests as the primary
statistical test.5,13,14,21
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Results
Most studies revealed improvements in outcome measures of depression from
baseline to follow-up, whether treated with telepsychiatry or face-to-face therapy,4-8,11-13
however, differences between groups were not statistically significant.5-9,12 Several
studies were able to conclude non-inferiority8,9 or equivalence4,5 of telepsychiatry to faceto-face treatment but no superiority study was able to conclude superiority of
telepsychiatry over face-to-face psychiatry.6-8
One possibility for these non-significant findings among the superiority studies
could be due to their utilization of remote locations for their treatment sessions, thus
negating the positive effects of remote sessions. The patients most in need of remote
telepsychiatry are often those who are homebound, chronically ill with comorbid diseases
and have difficulty ambulating and traveling to appointments. It is likely that this study
design did not allow for homebound individuals to take part in the study. Similarly, the
patient selection of all but one study4 did not allow for patient selection from the
population of homebound adults—rather, selection was limited to those who had
previously sought out and received healthcare services.
Other confounding factors found in our review included recruitment exclusively
from the VA healthcare system, resulting in a largely male and Caucasian participant
population.6,8,9 Furthermore, most studies did not focus on the elderly population, often
including participants over the age of 18 – only one study included participants over the
age of 65.11 Inclusion criteria was too broad in several cases12,14,16 or not
operationalized.16
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The most common interventions were psychotherapy (BATD8,9,11 or CBT10,13)
which were delivered by trained and experienced providers in all but one study, which
used graduate students with minimal training and no experience.16 Outcome measures
were varied, with HDS being the most commonly used.3,4,6,10,15 The technology was
similar in most studies, utilizing computer-based teleconferencing equipment connected
to the internet in all but one study which implemented an analogue phone.9
There are many studies in the literature focusing on patient satisfaction with
telepsychiatry. Although not the purpose of this review, some of the studies included in
the review did report satisfaction measurements as a secondary analysis. One study found
that homebound adults had higher approval rates of telepsychiatry than the face-to-face
treatment groups,4 another reported moderate satisfaction,5 and one study had no
difference in satisfaction.6 All three participants in the Lazzari et al.11 study reported
satisfaction with treatment by videoconferencing.
Conclusion
Based on a review of the literature, telepsychiatry is at least as effective as faceto-face therapy. However, more research on depression outcome measures targeted
specifically at older, homebound adults is needed. When studying older patient
populations, methods should be employed that will be most accessible to this population,
such as delivering treatments in the participant’s home as opposed to a clinic or off-site
study location. In addition, recruiting a more diverse population in both age, race and
gender is important to the external validity of the study.
Most importantly, our literature review concluded that there have been no studies
that specifically account for the physical abilities and limitations that are commonly
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encountered in older age. Controlling for hearing loss, impaired mobility and lack of
familiarity with technology is important since these variables all impact the effectiveness
of telepsychiatry delivery. In general, clinical studies tend to attract young and healthy
adults and often exclude those with disabilities. It is important to include participants
with disabilities so that interventions may be optimized to the complex populations they
are designed to treat. In particular, late-life psychiatric conditions tend to be more
complex and often co-morbid with other serious impairments, and it would be shortsighted to investigate the effectiveness telepsychiatry in elderly populations without
accounting for hearing loss, a common ailment found in this population.
Due to the limitations found in the literature, we propose a study aimed towards
the depressed, elderly population, who often suffer from presbycusis. We will to take this
disability into account when the designing study methodology by directly measuring
hearing loss and incorporating hearing devices into the remote treatment technology.
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Chapter 3 – Study Methods
Study Design
We will conduct a single-blind, randomized controlled trial powered to assess superiority
of telepsychiatry over traditional, face-to-face psychotherapy. The groups will be assessed for
depression using the Beck Depression Inventory II (BDI-II)1 at baseline (week 0), mid-treatment
(week 4) and post-treatment (week 8). The primary outcome is clinical improvements in
depression and the secondary outcome is patient satisfaction, assessed using the Charleston
Psychiatric Outpatient Satisfaction Survey (CPOSS)1 at post-treatment.
Outcome Measures
Primary Outcomes
The primary outcome measure will be the numerical change in BDI-II scores from
baseline to post-treatment for each participant. BDI-II is a 21-item, self-reported, multiple-choice
inventory that is a widely used indicator for the severity of depression. Each answer is scaled on
a range of 0 to 3. Sum scores range from 0 to 63 with higher scores indicating increased
depression severity. A score of 0 to 10 is categorized as “normal,” 11 to 16 as “mild mood
disturbance,” 17 to 20 as “borderline clinical depression,” 21 to 30 as “moderate depression,” 31
to 40 as “severe depression” and over 40 is considered “extreme depression.” The BDI-II has
good internal consistency (a=0.91)2 and high validity and is sensitive to change.3
Changes in BDI-II scores in the telepsychiatry group will be compared to the face-to-face
group. We hypothesize that there will be a clinically significant difference in pre-treatment to
post-treatment scores between the experimental and control groups.
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Secondary Outcome
The secondary outcome measure is treatment satisfaction measured at mid-treatment and
post-treatment using the CPOSS. The CPOSS is a 16-item Likert-scale response format that
measures a patient’s satisfaction with his or her treatment. Scores range from 13 to 65, with
higher scores representing increased satisfaction with treatment. We hypothesize that participants
in the telepsychiatry group will have higher scores than those in the face-to-face group at both
mid-treatment and post-treatment. We will also assess how the level of presbycusis affects
clinical outcomes and patient satisfaction by correlating the level of presbycusis (discussed under
“Hearing Loss” in “Study Variables and Measures” section) to BDI-II scores and CPOSS scores.
Study Population and Sampling
Study participants are male and female veterans and non-veterans. Veterans will be
recruited from the VA mental health and primary care clinics; non-veterans are referred from
healthcare professionals, self-referred via posted fliers in the community, or through agencies
serving seniors in their homes. Inclusion criteria are as follows: participants aged 60 or older
who—based on the Structured Clinical Interview (SCL) for the DSM-IV Axis I Disorders4—meet
the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV)5 criteria for the
following mood disorders: major depression disorder (MDD), mood disorder due to a general
medical condition, adjustment disorder with depressed mood, dysthymic disorder (DD) or
depression disorder not otherwise specified (NOS). Participants must score a 11 or greater on the
Beck Depression Inventory II, indicating a depression severity of mild and above.6 They also
must have age-related hearing loss as assessed using pure tone audiometry7 as well as have
access to high speed internet in their home. Participants will be excluded if they have a DSM-IV
diagnosis of psychosis, dementia, suicidal ideation with clear intent, substance dependence,
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cognitive impairment (Montreal Cognitive Impairment Assessment8 score of less than 26), if
their living situation does not permit a private area for sessions to take place or if their corrected
hearing in both ears does not allow them to hear below 90 dB, measured with pure tone
audiometry.
Recruitment
We will use three methods for recruitment for eligible subjects. The first method will be
an IRB approved sampling method in which we will systematically identify patients with any of
the following diagnosis: MDD, mood disorder due to a general medical condition, adjustment
disorder with depressed mood, dysthymic disorder or depression disorder not otherwise specified
using the Veterans Affairs Connecticut Health Care (VACT) clinic billing records over the
previous 12-months. We will contact providers of eligible patients in order to request permission
to contact their patients regarding study enrollment. We will mail invitation letters to eligible
patients. The letter will specify our interest in recruiting individuals with hearing loss and
depression. The recruitment letter will include the following: information about the study,
eligibility requirements, an addressed, stamped postcard that potential participants can return to
indicate interest or decline participation in the study, and a phone number that participants can
contact to obtain more information about the study, to make an appointment for study assessment
or to decline the invitation. The letter will also inform the subject that they will receive a followup phone call in two weeks if they have not returned the post-card or have not called to accept or
decline the invitation. Once patients agree to participate, they will be asked to provide written
consent and will be scheduled for a screening assessment.
The second method will be a convenient sampling through self and provider referrals.
IRB approved fliers will be placed at prominent locations outside of VA primary care clinics,
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primary care health clinics in CT and at senior centers throughout New Haven and surrounding
communities. The fliers will describe the study and its eligibility requirements, as well as provide
an email and phone number for subjects to contact if interested. The fliers will also be provided
to clinicians who may refer patients to the study at their discretion. Clinicians may also obtain
verbal consent from patients for study personnel to contact them. Furthermore, we will present
the study, its aims and subject requirements at physician and clinic staff meetings at the VACT
and community primary care sites to encourage referral of eligible subjects.
The final method of recruitment will be through the senior agencies such as Meals on
Wheels, Senior Dine Program and “My Ride” transit. We will use IRB approved methods to
systematically identify potential participants who meet the age criteria through the agencies
records and send invitations to participate in our study. Participants interested in participating
can then contact researchers who will answer any additional questions and schedule participants
for an initial screening session.
Screening and Baseline Questionnaires
Once participants have agreed to participate, they will complete a written informed
consent and undergo a baseline screening for depression, cognitive impairment, other psychiatric
comorbidities and hearing loss. The baseline interview at week 0 will include a demographic
questionnaire, a Montreal Cognitive Assessment (MoCA) screen, a structured clinical interview
for DSM-IV (SCID-IV), the Beck Depression Inventory II (BDI-II) assessment, and a pure tone
audiometry test. We will also ensure that patients taking antidepressants will be stabilized for 4
weeks prior to initiating study treatment and will ask that providers maintain dosage, if possible,
throughout the 8 weeks of the study.
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Demographic Questionnaire
Demographic information will include age, race/ethnicity, occupation/work status, level
of education, family income, living situation, marital status, branch of military service (if
applicable), number of diagnosed chronic illnesses, number of diagnosed psychiatric illnesses,
previous mental health treatment and number of medications including class of medications (e.g.
antidepressants, sedative hypnotics, antipsychotics, mood stabilizers, stimulants, antianxiolytics).
Montreal Cognitive Assessment (MoCA)8
The MoCA is a widely used screening tool for detecting cognitive impairment by
assessing short-term memory, visuospatial abilities, attention, language and orientation. The test
is scored from 0 to 30, with a score of 26 or over considered normal. Scores below 26 indicate
cognitive impairment. The MoCA has good convergent validity and was superior to its
counterpart exam, the Mini Mental Status Exam, in this regard.9
Structured Clinical Interview for DSM-IV (SCID)4
The SCID is a semi-structured interview that is considered the “gold standard” in
diagnosing psychiatric disorders. The interview is performed by clinicians and incorporates
current and past major depressive episodes, manic and hypomanic episodes, delusions,
hallucinations as well as substance use disorders. The interview has been shown to have
excellent validity.10
Beck Depression Inventory II6
Participants must score an 11 or greater on the Beck Depression Inventory II, indicating a
depression severity of mild and above.6 Participants will complete the BDI-II questionnaire at the
screening interview and at the end of their 4th and 8th sessions and will remain in the office or
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online with the clinician until the questionnaire is screened by the clinician for suicidal ideations
(SI). If a participant responds to the suicidal thoughts or wishes question (question #9) as either
“I have thoughts of killing myself, but I would not carry them out,” “I would like to kill myself,”
or “I would kill myself if I had the chance to,” then researchers will inform the primary
investigator (PI) who will speak with the patient via the phone, assess the subject’s safety, and if
indicated, activate the local emergency medical service (EMS) to bring the patient to the closest
emergency room for further evaluation. If the subject is physically present and endorses a
positive response on item #9 of the BDI-II, the PI will meet with the subject, assess the subject’s
safety and escort the patient to the onsite emergency room for further evaluation, if required.
Pure Tone Audiometry (PTA) Test
The PTA test is the “gold standard” hearing test used to identify the decibel threshold at
which an individual is able to hear. Patients are asked to indicate when they hear the “beep” of
the machine. The resulting shape of the audiogram gives an indication of the type of hearing loss.
In our study, uncorrected and corrected hearing loss will be assessed as described in the “Study
Variables and Measures” section below. Participants will be excluded if they are able to hear
below 25 decibels without correction (considered “normal” hearing) or if they are unable to hear
below 70 decibels with correction in both ears. PTA is a valid test among older adults even
without the use of a sound-treated environment.11
Methodology
Randomization
A senior biostatistician will randomly assign participants into either control or
experimental groups and provide the study coordinator with the assignments in individualized,
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sealed envelopes. This information will remain confidential in order to provide the study with a
single-blind design.
Blinding
Due to the nature of the study design, neither the participants nor the clinicians providing
the intervention will be blinded to the intervention. However, the researchers collecting the
outcome data and baseline assessments will not be aware of the treatment condition, making this
a single blind study.
Data Collection
We will use a secure, password protected electronic database to document participants’
medical and psychiatric diagnosis’, hearing assessments and questionnaires. In addition to
baseline questionnaires and assessments, participants will repeat the BDI-II assessment at midtreatment and post-treatment. The CPOSS survey will be completed at mid-treatment and posttreatment.
Table 5. Data Collection Protocol

Baseline
(week 0)
Mid-Treatment
(week 4)
Post-Treatment
(week 8)

Demographic
Questionnaire
X

SCID
Interview
X

MoCA

PTA

BDI-II

X

X

X

CPOSS

X

X

X

X

Participant Protection and Confidentiality
This proposal will be submitted for review to the VA and Yale Institutional Review
Board (IRB) before proceeding with the protocol described. In addition, we will submit an
application and supporting documents to the Human Subjects Committee (HSC) at the Yale
School of Medicine. Following submission of all material, all study personnel will undergo
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Health Insurance Portability and Accountability Act of 1996 (HIPAA) privacy training and
provide documentation of completion. Furthermore, all participants will be required to provide
informed consent in order to participate in the study. Participants will be provided with detailed
information regarding study protocols and any anticipated risks and benefits. They will be
informed that their participation is voluntary and may be terminated at any point if they choose
and their withdrawal will not affect their eligibility for future studies. Participants will not be
considered for the study if they are unwilling or unable to provide consent. Finally, in
accordance with state and federal law, all protected patient information will be securely stored
and accessed via a password-protected electronic database. No physical participant records will
be stored. All study personnel and clinicians will sign a confidentiality agreement.
Study Variables and Measures
Hearing loss
The Center for Disease Control (CDC) defines the degree of hearing loss as a specific
range of decibels (dB) that one can hear with their better ear. The CDC provides the following
widely accepted ranges of defined hearing loss:7
Table 6. Degree of Hearing Loss
Hearing Ability

Range (decibels)

Normal hearing

0-25

Mild hearing loss

26-40

Moderate hearing loss

41-55

Moderately severe hearing loss

56-70

Severe hearing loss

71-90

Clinically deaf

91+
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We will exclude normal hearing adults and condense the classifications into two groups
as defined as mild/moderate hearing loss ranging from 25 to 55 dB, and severe hearing loss
ranging from 56 to 90 dB. Participants will be assessed for corrected hearing loss with the use of
their own hearing aids or those provided to them through the study. They will be excluded if
their corrected hearing loss does not allow them to hear below 90 decibels.
Corrected Hearing Loss
Participants in the experimental group will be provided with Sony - ZX Series Wired On-Ear
Headphones.12 The headphones are designed to fit comfortably over existing hearing aids and
will allow for further sound amplification of the clinician during telepsychiatry sessions, while
also reducing unwanted ambient noise. The control group will not use headphones since they
will be receiving treatment in-person, however they will be permitted to use their own hearing
aids.
Psychotherapy Treatment
All participants will receive 8 weekly 60-minute depression treatment sessions. The
experimental group will receive sessions via telepsychiatry in their homes and the control group
will receive sessions face-to-face in the clinic. For the treatment of depression, we will use the
Behavioral Activation Treatment for Depression (BATD)13 method for both groups. The primary
outcome will be effectiveness of the BATD treatment measured by the Beck Depression
Inventory. The secondary outcome will be patient satisfaction with the treatment, measured by
the Charleston Psychiatric Outpatient Satisfaction Survey.1
Treatment Integrity
Twenty percent of the sessions will be audio recorded and rated independently by an
expert in BATD protocol to ensure treatment consistency and proper treatment administration.
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The expert reviewer will use a 7-point Likert scale rating form to assess how well the clinician
accomplished the various behavioral tasks throughout the session. In addition, clinicians will be
asked to rate themselves after each session using the same Likert scale as the expert reviewer.
Behavioral Activation Therapy for Depression (BATD)13
BATD is an efficient and effective depression treatment method which encourages
patients to identify activities and individuals that bring them joy, and to therefore maximize
contact with these sources. The therapy focuses on self-reflection through daily monitoring
worksheets, life areas assessment worksheets, life activities checklists and identification of
supportive people. It has good internal consistency, reliability and validity.14
BATD was developed as a shorter form of behavioral activation (BA) after seminal work
done by Lewinsohn (1974)15 found that the behavioral aspects of cognitive behavioral therapy
(CBT) performed as well as CBT as a whole.15 Additionally, BATD has been shown to be an
efficient and effective treatment for depression in adults13 and has been used in many
telepsychiatry studies to compare the effect of telepsychiatry BATD to in vivo BATD.16-19 The
fundamental aim of BATD therapy is to monitor daily activities in order to identify those
activities which bring the greatest joy and maximize time spent engaged in those pursuits.
In a meta-analysis of BADT consisting of 16 studies and 780 subjects, authors found a
large effect size of 0.87.20 When compared to cognitive behavioral therapy (CBT)21 and
antidepressants (paroxetine), it was found to be superior to CBT and comparable to
antidepressants.22 Studies have also shown that older adults prefer counseling over
antidepressants for the treatment of depression.23 Another form of depression psychotherapy is
Acceptance and Commitment Therapy (ACT)24 which is a based on the concept that a patient
will have sad feelings and should accept these feelings while continuing to live their life. ACT
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therapy does not focus on a functional assessment like BATD but places more value more on
acceptance of feelings. Compared to ACT, BATD is more action-focused and thus may be better
suited for the large portion of veterans in our sample size, the majority of which are men. It has
been demonstrated that men who suffer from depression are less likely to communicate problems
verbally and more likely to act out by working more, engaging in risky behaviors and/or turning
to alcohol or drugs.25 These action-oriented behaviors suggest that veterans may respond better
to action-oriented therapy compared to cognitive-oriented therapy. Lastly, compared to other
forms of psychotherapy, BATD is relatively simple, time-efficient and does not require complex
skills from the patient nor does it require intensive training of the therapist. For these reasons, we
concluded that BATD would be the best treatment modality for our study.
The revised manual of BATD consists of 5 treatment sessions with an additional 5
sessions to review concepts and engage in post-treatment planning. Although there has been no
formal systematic comparison of BATD treatment length and its efficacy, 10 sessions is a
standard length, with even shorter protocols producing benefits.26,27 Our study will use 8
sessions.
Beck Depression Inventory II (BDI-II)6
The BDI-II consists of 21 questions scored on a scale of 0 to 3 with higher scores
indicating more severe depression. It is the most widely used self-reported depression inventory
tools in use. It has a Pearson r of .71 correlation with the Hamilton Depression Rating Scale and
a one-week test-retest rating of Pearson r of .93, making it a very effective tool among selfreported measurement instruments.6 The internal consistency was rated high (a=0.89) among
geriatric patients as well.28
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Although the BDI-II measurement has good reliability and consistency, it is still
vulnerable to patient exaggeration or minimization because it is a self-reported measure.
However, we expect this confounding factor to be minimized since our study will be comparing
scores from pre-treatment to post-treatment among the same individuals.
Charleston Psychiatric Outpatient Satisfaction Survey (CPOSS)1
The CPOSS is a 16-item Likert-scale response survey that measures a patient’s
satisfaction with their treatment. Scores range from 13 to 65, with higher scores representing
increased satisfaction with treatment. In a sample population, Egede et al. (2009), found that this
measure had excellent reliability (Cronback’s alpha = 0.96) and good validity with relevant
anchor items (“would you recommend this treatment to a friend or family member?”) among
elderly veterans treated for depression through telepsychiatry.29 Although some of the items on
the scale are only relevant to clinic-based practices, there is an “Not Applicable” option and
scores will be calculated by blinded researchers in order to take these answers into account.
Sample Size Calculation
We would like to demonstrate superiority of telepsychiatry compared to face-to-face
psychotherapy among geriatric participants with presbycusis. The primary outcome measure is
the numerical difference in the BDI-II score from baseline to post-treatment. In order to calculate
the sample size required for this continuous outcome superiority trial, we used the previously
identified clinically significant effect size of 5 for the BDI-II30 with a standard deviation of ten.31
To achieve 80% power on a one-sided test to detect this difference with a significance level of
5%, it is estimated that 113 subjects per group would be required. After accounting for a 20%
drop-out rate, 137 subjects per group or a total of 274 subjects will be recruited (see Appendix I
for sample size calculation).
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Analysis
Inferential statistics will be used to compare the baseline characteristics of each group to
ensure adequate randomization. We will also report baseline characteristics as proportions for the
dichotomous variables and as means and standard deviations for the continuous variables. Prior
to analysis, we will implement a last observation carried forward (LOCF) method to compare
patients who dropped out to those who persisted in the study to ensure that there are not
significant differences between the groups.
Our null hypothesis is that depression treatment delivered via telepsychiatry is superior to
treatment delivered face-to-face among geriatrics patients suffering from presbycusis. The
primary outcome will be change in depression score, measured by the BDI-II, between baseline
and post-treatment. Using a univariate method, we will compare the differences in baseline and
post-treatment depression scores between treatment and control groups using a T-test.
Additionally, following the design of similar studies in the literature, the primary outcome
measure will be analyzed using a linear mixed effects model. This is often preferable to
univariate analysis because it allows us to control for potential confounding factors and to better
understand the trajectory of depression scores over multiple measurements (baseline, midtreatment and post-treatment).
To model this, we will consider the baseline, mid-treatment and post-treatment measures
as “repeated measures” and construct a mixed effects model to assess the effect of treatment
group on depression score. In this model the dependent variable is depression score, and the key
independent variables are (1) treatment group, (2) time (measured in weeks since patient intake)
and (3) the interaction of treatment group and time. This will allow us to test both whether
treatment versus control group assignment impacted the final depression score, as well as
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whether patients in the treatment group improved at the same or different rate compared with
patients in the control group. This analytic method is well suited to this problem because we can
use patient background characteristics as covariates (including age, initial severity of depression
and severity of hearing loss) and because it allows us to investigate the trajectory of depression
scores over time.
Timeline and Resources
Timeline
Study personnel will be recruited four months before initiation of the start of subject
recruitment and will undergo personnel-specific training as described below. We expect
participant recruitment to commence in October of 2019 and continue until October of 2020.
Participants will begin the 16-week study treatment on a rolling basis, with the last treatment
scheduled to end by March 2020. Data entry will be completed on a rolling basis, and analysis is
expected to be completed by June 2020. Completion of the study, which includes study
personnel training, recruitment, therapeutic intervention and data analysis will take 24 months in
total.
Research Assistants
Research assistants (RA) will be volunteer senior psychology majors or graduate
psychology students recruited by the psychology department at Yale University through fliers
and student interest group postings. We will recruit 5 to 6 RA’s and their responsibilities will
include placement of fliers as directed by the study coordinator, as well as receiving calls from
potential participants, providing them with information about the study, directing calls to the PI
or Co-PI when necessary and inputting data into our database.
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Senior Biostatistician
This role will be filled by a volunteer biostatistician who will have a minimum of two
years of experience as a biostatistician with experience working in a research setting. The
biostatistician will provide randomized participant assignments to the study coordinator in a
blinded fashion. He/she will also be available to the PI for statistical consultation during the
analysis phase.
Study Coordinator
The study coordinator will be the Principle Investigator (PI) and will be responsible for
ensuring all study personnel complete their required training and will be available to support
their responsibilities. They will not be involved in data gathering or treatments and will remain
blind to the conditions throughout the study. The PI will be a licensed independent practitioner,
qualified to assess a participants’ physical health, psychological status and suicidality.
Treatment Clinicians
Four to five board certified clinical psychologists with at least three years of clinical
experience will be recruited from clinicians working at the VA or in the community through
fliers and emails. They will undergo a two-week training course on BATD as well as training on
the remote software. Their main responsibility will be to provide BATD to study participants.
Outcome Measures Clinicians
Three to four board certified clinical psychologists with at least three years of clinical
experience will be recruited from clinicians practicing at the VA or in the community to
complete all initial SCID and MoCA evaluations. Initial screening and baseline measurement
will be completed in the clinic for all participants, thus blinding clinicians to treatment
conditions. The mid-treatment and post-treatment measurements (BDI-II and CPOSS) will be
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completed by participants after their 4th and 8th sessions while clinicians remain on-line or in the
clinic. Clinicians will review the BDI-II question number 9 (assessing for suicidality), before
ending the session with the participant, and will take further action by informing the PI if the
study participant screens positive for SI. All study personnel will be required to complete
HIPAA training and to sign a confidentiality agreement.
Videoconferencing Equipment
Google’s Duo videoconferencing system will be used for telepsychiatry sessions. The system
is optimized for low bandwidth networks and provides high-definition video calls. It also offers
default end-to-end encryption for safety and privacy.32 Inclusion criteria includes access to a
computer in the home as well as high speed-internet (defined as having an Integrated Services
Digital Network (ISDN) or Digital Subscriber Line (DSL) connection). Therefore, set-up for
Google’s Duo’s videoconferencing system will only require participants to navigate to the
website, enter their phone number, and enter the system-provided verification code sent to the
participant’s phone.
Sound Amplifiers
The experimental group will be provided with Sony - ZX Series Wired On-Ear
Headphones12 which will amplify the telepsychiatry sessions. Participants will be able to wear
their own hearing-aides simultaneously.
Research Staff Workroom
Several private rooms in VACT or Yale Medical School will be designated for clinical
outcome measure interviews, questionnaires and telepsychiatry sessions.
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Chapter 4 – Conclusion
Telepsychiatry is an expanding field but many studies have focused on patient
satisfaction rather than outcome measures. Furthermore, of those that investigate outcome
measures, few include the geriatric population, even though this population is growing and may
be particularly in need of remote treatment for chronic illnesses such as depression. Geriatric
patients have more difficulty coordinating transportation to appointments, may be geographically
isolated, and have age-related physical impairments which may make the delivery of healthcare
more accessible when provided remotely. Our study focuses on outcomes among this
disadvantaged population of older adults with age related hearing loss.
Advantages and Disadvantages
Our study specifically measures hearing loss as a confounding variable using pure tone
audiometry, a method that has not been used before and will be vital in providing information on
the impact hearing loss has on the success of telepsychiatry among geriatric patients. We have
chosen to exclude patients who are clinically deaf as this population requires a different set of
interventions such as American Sign Language (ASL) interpreters; fortunately, there is another
set of literature addressing this population.1,2 Furthermore, to ensure patient diversity, we have
recruited subjects from the VA hospital, connunity primary care clinics and senior agencies with
the goal of expanding our study population to elderly who are homebound and may not be
currently receiving medical care. We also plan to provide our telepsychiatry intervention in the
participants home. While this design does not allow for a carefully controlled setting, it will
allow us to appreciate the effectiveness of the intervention in vivo.
There are several limitations in our study. First, although our sample size is large enough
to detect superiority of telepsychiatry to face-to-face therapy, it may be too large to recruit and
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complete the study in a two-year timeframe and more time may be needed to recruit patients.
Second, the sample size also may not be large enough to detect the association between levels of
presbycusis and outcome measures. Third, a third arm ideally would be added to the design,
representing a “true” control that would allow us to not only compare telepsychiatry to face-toface depression treatment but also to compare it to a placebo-like interaction such as support
calls. However, adding a third arm dramatically increases the sample size required to detect
significance between groups and would not be feasible within our limited timeline and resources.
Since we do not want to confound any treatment of depression with the specific remote
intervention we are implementing, we have chosen to compare our intervention to the standard
treatment protocol as opposed to a placebo treatment.
Fourth, our study is a single-blind study because it is not possible to blind the participants
to the intervention of telepsychiatry or face-to-face psychiatry. While a double-blind study is
ideal, our intervention presents limitations in this regard. Nevertheless, we have blinded
assessors and researchers to treatment conditions at all other data collection points. A fifth
limitation is the lack of follow-up. Ideally, a lengthy follow-up period would allow us to
determine the long-term outcomes of telepsychiatry treatment.
Public Health Significance
Overall, this study represents a novel contribution to the field through its focus on the
provision of telepsychiatry in hearing impaired older adults and its recruitment of a diverse
patient population. The evidence that the elderly population is accepting of a videoconferencing
as a form of therapy3 means that such a method is scalable to meet the needs of this population.
As the field of telemedicine grows, the technology will be become cheaper and more accessible
to both patients and providers. However, Medicare only reimburses for telepsychiatry when
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delivered to designated rural-area residents.4 Thus, the policies surrounding Medicare
reimbursement for telemedicine services should be addressed and include disadvantaged
populations such as the elderly and homebound individuals. The results of our study will impact
future therapies directed towards older adults and contribute to the growing support of
telepsychiatry and the populations it aims to serve.
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Appendix A
Form 1. Invitation to Potential Participants
Hi, my name is Stephanie Mock and I am a graduate from the Yale University Physician
Associate program. I am conducting a research study to examine the impact of therapy
(Behavioral Activation Treatment for Depression (BATD)) on older individuals suffering from
depression and hearing loss. Our records indicate that you are a potential candidate for our study.
Participation in this study will involve completing baseline questionnaires, a complete hearing
evaluation, and follow-up questionnaires at the end of the study. The majority of your time will
be involve participating in either online (from your home) or in-person psychotherapy sessions
with a licensed clinical psychologist. These will consist of 8 weekly 1-hour sessions and include
weekly assignments, daily journals and thoughtful discussion with the clinician. Your
involvement will require about 1 hour/week for 10 weeks. You will not be expected to pay for
the therapy sessions, nor will you be compensated for your participation.
The ideal candidate for participation in this study is one who has access to high speed internet,
has a private space in the home, has some trouble hearing in one or both ears, and suffers from
depression.
If you are interested in finding out more about this study, please call one of our researchers at
###-###-####.
If you know whether or not you would like to participate in this study, please indicate so on the
attached form and send using the pre-addressed and stamped post-card. You may also call the
number above to indicate your interest or disinterest. If we do not receive a response within 2
weeks, we will call to confirm your response to the invitation.

Thank you for your consideration,
Stephanie Mock
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Appendix B
Figure 1. Psychologist and Research Assistant Recruitment Fliers

RESEARCH
ASSISTANTS
needed to support a
TELELMEDICINE
study
Our study is evaluating various outcomes in
depressed geriatric participants with presbycusis
(hearing loss) who are treated with Behavioral
Activation Therapy for Depression via
telepsychiatry. We are seeking research assistants for
data entry and interviewing potential subjects. Ideal
candidates will be senior psychology majors or
graduate psychology students. Please email
stephanie.mock@yale.edu for more information.

CLINICAL
PSYCHOLOGISTS
needed to participate
in a
TELEMEDICINE
study
Our study is evaluating various outcomes in
depressed geriatric participants with presbycusis
(hearing loss) who are treated with Behavioral
Activation Therapy for Depression (BATD) via
telepsychiatry. We are seeking clinical psychologists
to provide BATD in person or through
telepsychiatry. Please email
stephanie.mock@yale.edu for more information.
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Appendix C
Form 2. Informed Consent
Title: Effectiveness of Telepsychiatry Among Geriatrics with Age-Related Hearing Loss

Researcher(s):

Stephanie Mock, Yale Physician Associate Program
Michelle Conroy, MD Yale School of Medicine

Researcher Contact Info: ###-###-####
stephanie.mock@yale.edu
You are being asked to participate in a research study. The box below highlights key information
about this research for you to consider when making a decision about whether or not to
participate. Carefully consider this information and the more detailed information provided
below the box. Please ask questions about any of the information you do not understand before
you decide whether to participate.
Key Information for You to Consider
•

•
•
•

•
•
•

Voluntary Consent. You are being asked to volunteer for a research study. It is
up to you whether you choose to participate or not. There will be no penalty or
loss of benefits to which you are otherwise entitled if you choose not to
participate or discontinue participation.
Purpose. The purpose of this research is to assess effects that Behavioral
Activation Treatment for Depression (BATD) has on older individuals suffering
from depression and hearing loss.
Duration. It is expected that your participation will last 5 months.
Procedures and Activities. You will be asked to participate in 8 weekly online
or in-person BATD sessions with a trained clinician, to complete all aspects of
the treatment protocols, including but not limited to weekly assignments, daily
journals and thoughtful discussion with the clinician. You will also be asked to
complete questionnaires throughout the course of the study as well as complete
one full audiometric assessment at the start of the study.
Risks. Some of the foreseeable risks or discomforts of your participation include
discussion of topics that may cause emotional distress, suicidal ideations or
thought of harming others or yourself.
Benefits. Some of the benefits that may be expected include receiving treatment
for depression and learning how to cope with depression in the long-term.
Alternatives. Participation is voluntary and the only alternative is to not
participate.

The researcher(s) Stephanie Mock and Michelle Conroy from Yale University are asking for
your consent to this research.
The purpose of the research is to evaluate the effectiveness of depression therapy through
telepsychiatry among older adults suffering from hearing loss and depression. You are being
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asked to participate because you have met criteria for age, potential hearing loss and potential
depression diagnosis. About 150 people will take part in this research.
If you agree to be in this research, your participation will include: assessment of hearing loss,
baseline questionnaires to evaluate your physical and mental health, participate in depression
treatment with a trained clinician through videoconferencing in your home or at the study
headquarters.
We will tell you about any new information that may affect your willingness to continue
participation in this research.
What happens to the information collected for this research?

Information collected for this research will be used to compare to other participants’ information
in order to discern how differences in treatment may affect depression symptoms and how
differences in participant characteristics effect how they respond to treatment types.
How will my privacy and data confidentiality be protected?

We will take measures to protect your privacy including storing data in password protected
database. Despite taking steps to protect your privacy, we can never fully guarantee your privacy
will be protected.
Individuals and organization that conduct or monitor this research may be permitted access to
and inspect the research records. This may include access to your private information and
electronic medical records. These individuals and organizations include: the primary research
investigator, clinicians, staff biostatistician and research assistants. All study personnel will
undergo Health Insurance Portability and Accountability Act of 1996 (HIPAA) privacy training
and provide documentation of completion.
What if I want to stop participating in this research?

Taking part in this research study is your decision. Your participation in this study is voluntary.
You do not have to take part in this study, but if you do, you can stop at any time. You have the
right to choose not to participate in any study activity or completely withdraw from continued
participation at any point in this study without penalty or loss of benefits to which you are
otherwise entitled. Your decision whether or not to participate will not affect your relationship
with the researcher, Veterans Affairs, senior agencies or Yale University.
Who can answer my questions about this research?

If you have questions, concerns, or have experienced a research related injury, contact the
research team at:
Stephanie Mock
###-###-####
stephanie.mock@yale.edu
If you would like to talk with someone other than the researchers to discuss problems or
concerns, to discuss situations in the event that a member of the research team is not available, or
to discuss your rights as a research participant, you may contact the Yale University Human
Subjects Committee, 203-785-4688, human.subjects@yale.edu. Additional information is
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available at https://your.yale.edu/research-support/human-research/research-participants/rightsresearch-participant
STATEMENT OF CONSENT
I have had the opportunity to read and consider the information in this form. I have asked any
questions necessary to make a decision about my participation. I understand that I can ask
additional questions throughout my participation.
I understand that by signing below, I volunteer to participate in this research. I understand that I
am not waiving any legal rights. I have been provided with a copy of this consent form. I
understand that if my ability to consent or assent for myself changes, either I or my legal
representative may be asked to re-consent prior to my continued participation in this study.
I consent to participate in this study.

Name of Adult Participant

Signature of Adult Participant

Date

Researcher Signature (to be completed at time of informed consent)
I have explained the research to the participant and answered all of his/her questions. I believe
that he/she understands the information described in this consent form and freely consents to
participate.

Name of Research Team Member

Signature of Research Team Member
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Date

Appendix D
Form 3. Montreal Cognitive Assessment (MoCA)
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Appendix E
Form 4. Demographics and Psychiatric Questionnaire
Patient’s Name: _______________________________________________________________
Date of Birth: ____/____/____ Patient’s Birthplace:__________________ Sex: __M __F
Race: __ African-American __ Caucasian __ Hispanic __ Asian __ Other ______________
Who referred you this study? _________________________________________________

Have you ever received outpatient mental health treatment? __ No __ Yes
If yes, please list in order:
Clinician/ Doctor
Date(s) of Evaluation Type of Evaluation or Frequency of visits
or Treatment
Treatment

Have you ever received inpatient mental health treatment? __ No __ Yes
If yes, please list in order:
Hospital Name
Dates of Treatment
Reason for hospitalization

If you have ever taken psychiatric medications, please list them below: ‰ Not applicable Rx
Name
Reason Given Highest Dose %
Side-effects
Dates
Improvement
Taken

Have you ever had any brain imaging or functional studies? (MRI, CAT scan, EEG, etc.)
__ No __ Yes
Substance Use History
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Please describe your past or current use of any of the following substances:
__ Never tried any Substance
Substance

Age at 1st use

Frequency of
use

Amount used

Last use

Problems
(physical, legal,
occupation,
relationships,
etc.)

ALCOHOL
TOBACCO
MARIJUANA
COCAINE
AMPHETAMINE
ECSTACY
LSD/ ACID
OPIATES
INHALANTS
HALLUCINOGENS
(mushrooms, PCP,
etc)

Have you ever received inpatient or outpatient substance abuse treatment? __ No __ Yes
Medical History
Who is your Internist or Family Doctor?
__ Do not have a doctor
________________________________________________
When was your last physical examination?
______________________________________________
Current Medications (include Over-the-counter meds, Vitamins, Herbs, or Supplements)
__ None OR Please List:
Rx Name
Dosage
Frequency
Prescribing M.D.

Do you have any drug allergies? ………………………………__ No __ Yes (please list):
______________________________________________________________________________
Do you have any current medical problems? ………………….__ No __ Yes (please list):
______________________________________________________________________________
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Social History
City of Residence: _____________________________
Now Living with: __ Spouse __ Children __ Roommate __ Other:_____________________
Marital status: __ Single __ Separated __ Divorced __ Married (How long?)_______________
Employment
Occupation:____________________________________________________________________
Work Status:
___ Employed

___Retired

___Unemployed

___On disability

___Other

If “Other” please explain: ________________________________________________________
School History
Highest grade level completed: ______
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Appendix F
Form 5. BATD Schedule of Treatment
1. Session 1
a. Introduction
b. Discussion of Depression
c. Introduction to Treatment Rationale
i. What about trauma and loss in your life?
ii. Why is coming every week important?
d. Introduce Daily Monitoring (Form 1)
i. Importance and Enjoyment Ratings
e. Introduce and Complete Contracts Part 1: Identifying Supportive People (Form 2:
Top Part)
f. Important Points about the Structure of This Treatment
2. Session Two
a. Review Daily Monitoring (Form 1)
b. Review Contracts Part 1: Identifying Supportive People (Form 2: Top Part)
c. Introduce and Complete Life Areas and Values (Form 3)
3. Session Three
a. Review Daily Monitoring (Form 1)
b. Review and Edit Life Areas and Values (Form 3)
c. Introduce and Complete Life Activities Checklist (Form 4)
4. Session Four
a. Review Daily Monitoring (Form 1)
b. Review Life Activities Checklist (Form 4)
c. Introduce and Complete Activity Selection and Ranking (Form 5)
d. Introduce and Complete Activity Hierarchy (Form 6)
5. Session Five

a. Review Daily Monitoring (Form 1)
b. Review and Edit Activity Selection and Ranking (Form 5)
c. Review and Edit Activity Hierarchy (Form 6)
d. Introduce and Complete Activity Planning (Form 1)
6. Session Six
a. Review Daily Monitoring (Form 1)
b. Review and Complete Activity Planning (Form 1)
c. Introduce and Complete Contracts Part 2: Getting Help from Supportive People
(Form 2: Bottom Part)
7. Session Seven
a. Review Daily Monitoring with Activity Planning (Form 1)
b. Review and Edit Contracts Part 2: Getting Help from Supportive People (Form 2:
Bottom Part)
c. Review and Complete Activity Planning (Form 1)
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d. Review Daily Monitoring with Activity Planning (Form 1)
e. Review Concept and Edit Activities (Forms 4, 5, and 6)
f. Complete Activity Planning (Form 1)
g. Review Concept and Edit Contracts (Form 2: Top and Bottom Part)
h. Complete Activity Planning (Form 1)
8. Session Eight
a.
b.
c.
d.

Review Daily Monitoring with Activity Planning (Form 1)
Review Concept and Edit Life Areas and Values (Form 3)
Complete Activity Planning (Form 1)
Prepare for Termination: Continuation of Daily Monitoring with Activity
Planning (Form 1)

List of Forms
Form 1. Daily Monitoring (with Activity Planning starting in Session 6)
o Therapist Manual: One copy
o Patient Manual: 84 copies (one for each day of treatment)
Form 2. Contracts
o Therapist Manual: One copy
o Patient Manual: 10 copies
Form 3. Life Areas Assessment
o Therapist Manual: One copy
o Patient Manual: One copy
Form 4. Life Activities Checklist
o Therapist Manual: One copy
o Patient Manual: One copy
Form 5. Activity Difficulty Assessment
o Therapist Manual: One copy
o Patient Manual: One copy
Form 6. Activity Hierarchy
o Therapist Manual: One copy
o Patient Manual: One copy
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Appendix G
Form 6. BDI - II
Instructions: This questionnaire consists of 21 groups of statements. Please read each
group of statements carefully. And then pick out the one statement in each group that
best describes the way you have been feeling during the past two weeks, including
today. Circle the number beside the statement you have picked. If several statements in
the group seem to apply equally well, circle the highest number for that group. Be sure
that you do not choose more than one statement for any group, including Item 16
(Changes in Sleeping Pattern) or Item 18 (Changes in Appetite).
1. Sadness
0. I do not feel sad.
1. I feel sad much of the time.
2. I am sad all the time.
3. I am so sad or unhappy that I can't stand it.
2. Pessimism
0. I am not discouraged about my future.
1. I feel more discouraged about my future than I used to.
2. I do not expect things to work out for me.
3. I feel my future is hopeless and will only get worse.
3. Past Failure
0. I do not feel like a failure.
1. I have failed more than I should have.
2. As I look back, I see a lot of failures.
3. I feel I am a total failure as a person.
4. Loss of Pleasure
0. I get as much pleasure as I ever did from the things I enjoy.
1. I don't enjoy things as much as I used to.
2. I get very little pleasure from the things I used to enjoy.
3. I can't get any pleasure from the things I used to enjoy.
5. Guilty Feelings
0. I don't feel particularly guilty.
1. I feel guilty over many things I have done or should have done.
2. I feel quite guilty most of the time.
3. I feel guilty all of the time.
6. Punishment Feelings
0. I don't feel I am being punished.
1. I feel I may be punished.
2. I expect to be punished.
3. I feel I am being punished.
7. Self-Dislike
0. I feel the same about myself as ever.
1. I have lost confidence in myself.
2. I am disappointed in myself.
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3. I dislike myself.
8. Self-Criticalness
0. I don't criticize or blame myself more than usual.
1. I am more critical of myself than I used to be.
2. I criticize myself for all of my faults.
3. I blame myself for everything bad that happens.
9. Suicidal Thoughts or Wishes
0. I don't have any thoughts of killing myself.
1. I have thoughts of killing myself, but I would not carry them out.
2. I would like to kill myself.
3. I would kill myself if I had the chance.
10. Crying
0. I don't cry any more than I used to.
1. I cry more than I used to.
2. I cry over every little thing.
3. I feel like crying, but I can't.
11. Agitation
0. I am no more restless or wound up than usual.
1. I feel more restless or wound up than usual.
2. I am so restless or agitated, it's hard to stay still.
3. I am so restless or agitated that I have to keep moving or doing something.
12. Loss of Interest
0. I have not lost interest in other people or activities.
1. I am less interested in other people or things than before.
2. I have lost most of my interest in other people or things.
3. It's hard to get interested in anything.
13. Indecisiveness
0. I make decisions about as well as ever.
1. I find it more difficult to make decisions than usual.
2. I have much greater difficulty in making decisions than I used to.
3. I have trouble making any decisions.
14. Worthlessness
0. I do not feel I am worthless.
1. I don't consider myself as worthwhile and useful as I used to.
2. I feel more worthless as compared to others.
3. I feel utterly worthless.
15. Loss of Energy
0. I have as much energy as ever.
1. I have less energy than I used to have.
2. I don't have enough energy to do very much.
3. I don't have enough energy to do anything.
16. Changes in Sleeping Pattern
0. I have not experienced any change in my sleeping.
1a I sleep somewhat more than usual.
1b I sleep somewhat less than usual.
2a I sleep a lot more than usual.
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2b I sleep a lot less than usual.
3a I sleep most of the day.
3b I wake up 1-2 hours early and can't get back to sleep.
17. Irritability
0. I am not more irritable than usual.
1. I am more irritable than usual.
2. I am much more irritable than usual.
3. I am irritable all the time.
18. Changes in Appetite
0. I have not experienced any change in my appetite.
1a My appetite is somewhat less than usual.
1b My appetite is somewhat greater than usual.
2a My appetite is much less than before.
2b My appetite is much greater than usual.
3a I have no appetite at all.
3b I crave food all the time.
19. Concentration Difficulty
0. I can concentrate as well as ever.
1. I can't concentrate as well as usual.
2. It's hard to keep my mind on anything for very long.
3. I find I can't concentrate on anything.
20. Tiredness or Fatigue
0. I am no more tired or fatigued than usual.
1. I get more tired or fatigued more easily than usual.
2. I am too tired or fatigued to do a lot of the things I used to do.
3. I am too tired or fatigued to do most of the things I used to do.
21. Loss of Interest in Sex
0. I have not noticed any recent change in my interest in sex.
1. I am less interested in sex than I used to be.
2. I am much less interested in sex now.
3. I have lost interest in sex completely.
Total Score: _______
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Appendix H
Form 7. Charleston Psychiatric Outpatient Satisfaction Scale
Your opinions about us are very important. Please give your honest opinions on each question.
Please rate each item on the following scale: EXCELLENT, VERY GOOD, GOOD, FAIR, or
POOR. If an item does not apply to you, circle DOES NOT APPLY (N/A).

1. Helpfulness of the secretary
2. Information provided about payment for
services
3. Amount of time waiting to be seen
4. Amount of information given to you about
your problem
5. Respect shown for your opinions about
treatment
6. Matching of treatment plan to your individual
needs
7. Helpfulness of the services you have received
8. Overall quality of care provided
9. Appearance of the waiting room
10. Appearance of the office
11. Office hours
12. Location of this outpatient service
13. Parking
14. Clear and correct monthly bill
15. Would you recommend this program to a
friend or family member? (circle one)

Very
Good

Excellent

Good

Fair

Poor

Does Not
Apply

5
5

4
4

3
3

2
2

1
1

N/A
N/A

5
5

4
4

3
3

2
2

1
1

N/A
N/A

5

4

3

2

1

N/A

5

4

3

2

1

N/A

5
5
5
5
5
5
5
5

4
4
4
4
4
4
4
4

3
3
3
3
3
3
3
3

2
2
2
2
2
2
2
2

1
1
1
1
1
1
1
1

N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Yes

No

Probably Not

Probably

Definitely

Definitely Not

How could we improve our services?
Other Comments:
Scoring the Charleston Psychiatric Outpatient Satisfaction Scale Items 1 through 14 are scored
using the following 5-point scale: 5 = Excellent 4 = Very good 3 = Good 2 = Fair 1 = Poor
Item 15 is scored using the following 4-point scale. 4 = Yes, definitely 3 = Yes, probably 2 = No,
probably not 1 = No, definitely not
The scale is scored by summing the scores of all individual items except the anchor items (items
8 and 15). The possible range is 13 to 65.
Copyright notice: The Charleston Psychiatric Outpatient Satisfaction Scale is copyrighted by Bartley C. Frueh, Ph.D. Permission has been
granted to reproduce the scale on this website for clinicians to use in their practice and for researchers to use in non-industry studies. For other
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uses of the scale, the owner of the copyright should be contacted. Citation: Pellegrin KL, Stuart GW, Maree B, Frueh BC, Ballenger JC. A brief
scale for assessing patients’ satisfaction with care in outpatient psychiatric services. Psychiatric Services 2001; 52:816-81

Appendix I
Form 8. Sample Size Calculation
Our sample size was calculated using the GLIMMPSE software created by University of
Colorado for sample size calculations for mixed effects models.1 Using a power of .80 and a type
1 error rate of 0.1, a total sample size of 226 was recommended (113 each in treatment and
control groups). The key assumption for this calculation was that over the course of the study
telepsychiatry patients’ improvements would be superior to face-to-face treatment by the
minimal clinically significant amount (5 points on the 60-point scale2). Furthermore, we assumed
that BDI has a standard deviation of 10.3
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